Abstract
The 2016 publication entitled “5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2 -positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial” in Lancet Oncology provided an opportunity to revisit the combination of pertuzumab and trastuzumab as a neoadjuvant treatment for HER2 -positive breast cancer (1). Pertuzumab is the first Food and Drug Administration (FDA)-approved drug in the neoadjuvant setting (2).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
